1200 Pharma
1200 Pharma LLC is a privately held pre-clinical drug discovery company founded in 2017 and headquartered in Culver City, California, with roots in Pasadena. It was launched by Caltech chemist Brian Stoltz, UCLA translational oncologist Dennis Slamon and chief executive David Licata, and it pairs Caltech medicinal-chemistry methodology with UCLA biomarker-driven screening assays to identify novel small-molecule oncology candidates — including KRAS and CDK inhibitors — at a fraction of the industry-average cost and timeline. The company employs roughly 20-50 people, has filed patents covering indole-based anti-cancer compounds, and has raised approximately $14.1 million from Kairos Ventures, Vest Coast Capital, OCV Partners, Alexandria Venture Investments, Pasadena Bio and the National Institutes of Health. Its product is drug intellectual property and discovery partnerships, not software: no developer program, public API, SDK, developer portal or machine-readable contract of any kind could be found, and no api/docs/developer hostname exists under its domain. At the time of profiling its only web property, 1200pharma.com, was not being served — the Cloudflare edge in front of it terminated every TLS handshake and answered plain HTTP with error 1001 — so the corporate site itself could not be read.
1200 Pharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Medicinal Chemistry.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.